前哨淋巴结活检在高危子宫内膜癌中的性能:系统评价与荟萃分析
该系统评价与荟萃分析纳入16项前瞻性队列研究,其中9项提供429例高危子宫内膜癌患者数据,评估前哨淋巴结活检(SLNB)联合吲哚菁绿宫颈注射的诊断性能。汇总每例检出率91%,双侧检出率64%,淋巴结阳性率26%,灵敏度92%,假阴性率8%,阴性预测值97%,结论认为SLNB可准确检出高危子宫内膜癌淋巴结转移,假阴性率与低级别子宫内膜癌及黑色素瘤、外阴癌、乳腺癌相当,可替代完整淋巴结清扫作为手术分期的标准。
要点
- 高危子宫内膜癌SLNB每例检出率91%,双侧检出率64%。
- SLNB灵敏度92%,假阴性率8%,阴性预测值97%。
- 作者认为SLNB可替代完整淋巴结清扫用于高危子宫内膜癌手术分期。
核心结论
- 前哨淋巴结活检能准确检出高危子宫内膜癌患者的淋巴结转移,假阴性率与低级别子宫内膜癌、黑色素瘤、外阴癌和乳腺癌相当。
- 这些发现提示前哨淋巴结活检可替代完整淋巴结清扫作为高危子宫内膜癌手术分期的标准。
研究设计与样本
- 系统评价与荟萃分析,检索MEDLINE、Cochrane Central Register of Controlled Trials、Cochrane Database of Systematic Reviews和Embase等数据库,检索时间2000年1月1日至2021年1月26日。
- 纳入前瞻性队列研究,对象为临床I期高危子宫内膜癌患者,采用吲哚菁绿宫颈注射检测前哨淋巴结,并以至少双侧盆腔淋巴结清扫为参考标准。
- 共纳入16项符合条件的研究,其中9项研究的作者提供了429例高危子宫内膜癌患者的专门数据。
- 研究水平中位年龄66岁(范围44-82.5岁),中位体重指数28.6 kg/m2(范围19.4-43.7 kg/m2)。
- 采用广义线性混合效应模型(logit)合并检出率和诊断准确性指标,使用QUADAS-2工具评估偏倚风险。
主要发现
- 汇总每例检出率为91%(95%CI 85%-95%;I2=59%),双侧检出率为64%(95%CI 53%-73%;I2=69%)。
- 总体淋巴结阳性率为26%(95%CI 19%-34%;I2=44%)。
- 87例淋巴结阳性患者中,前哨淋巴结活检正确识别80例,汇总每例灵敏度92%(95%CI 84%-96%;I2=0%)。
- 假阴性率为8%(95%CI 4%-16%;I2=0%),阴性预测值为97%(95%CI 95%-99%;I2=0%)。
关键数值与推荐
- 高危组织学类型包括:3级子宫内膜样癌、浆液性癌、透明细胞癌、癌肉瘤、混合性癌、未分化或去分化癌以及非特指型高级别癌。
- 前哨淋巴结检测采用吲哚菁绿宫颈注射。
- 参考标准为至少双侧盆腔淋巴结清扫。
临床怎么用
- 在高危子宫内膜癌患者的手术分期中,可考虑采用前哨淋巴结活检替代完整淋巴结清扫。
- 前哨淋巴结活检的假阴性率较低,阴性预测值高,有助于减少不必要的系统淋巴结清扫。
局限性
- 纳入研究为前瞻性队列研究,可能存在偏倚风险。
- 仅9项研究提供了高危子宫内膜癌患者的专门数据,样本量为429例。
- 研究间检出率存在异质性(每例检出率I2=59%,双侧检出率I2=69%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: A sentinel lymph node biopsy is widely accepted as the standard of care for surgical staging in low-grade endometrial cancer, but its value in high-grade endometrial cancer remains controversial. The aim of this systematic review and meta-analysis was to evaluate the performance characteristics of sentinel lymph node biopsy in patients with endometrial cancer with high-grade histology (registered in the International Prospective Register of Systematic Reviews with identifying number CRD42020160280). DATA SOURCES: We systematically searched the MEDLINE, Epub Ahead of Print, MEDLINE In-Process & Other Non-Indexed Citations, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Embase databases all through the OvidSP platform. The search was performed between January 1, 2000, and January 26, 2021. ClinicalTrials.gov was searched to identify ongoing registered clinical trials. STUDY ELIGIBILITY CRITERIA: We included prospective cohort studies in which sentinel lymph node biopsy were evaluated in clinical stage I patients with high-grade endometrial cancer (grade 3 endometrioid, serous, clear cell, carcinosarcoma, mixed, undifferentiated or dedifferentiated, and high-grade not otherwise specified) with a cervical injection of indocyanine green for sentinel lymph node detection and at least a bilateral pelvic lymphadenectomy as a reference standard. If the data were not reported specifically for patients with high-grade histology, the authors were contacted for aggregate data. METHODS: We pooled the detection rates and measures of diagnostic accuracy using a generalized linear mixed-effects model with a logit and assessed the risk of bias using the Quality Assessment of Diagnostic Accuracy Studies 2 tool. RESULTS: We identified 16 eligible studies of which the authors for 9 of the studies provided data on 429 patients with high-grade endometrial cancer specifically. The study-level median age was 66 years (range, 44-82.5 years) and the study-level median body mass index was 28.6 kg/m2 (range, 19.4-43.7 kg/m2). The pooled detection rates were 91% per patient (95% confidence interval, 85%-95%; I2=59%) and 64% bilaterally (95% confidence interval, 53%-73%; I2=69%). The overall node positivity rate was 26% (95% confidence interval, 19%-34%; I2=44%). Of the 87 patients with positive node results, a sentinel lymph node biopsy correctly identified 80, yielding a pooled sensitivity of 92% per patient (95% confidence interval, 84%-96%; I2=0%), a false negative rate of 8% (95% confidence interval, 4%-16%; I2=0%), and a negative predictive value of 97% (95% confidence interval, 95%-99%; I2=0%). CONCLUSION: Sentinel lymph node biopsy accurately detect lymph node metastases in patients with high-grade endometrial cancer with a false negative rate comparable with that observed in low-grade endometrial cancer, melanoma, vulvar cancer, and breast cancer. These findings suggest that sentinel lymph node biopsy can replace complete lymphadenectomies as the standard of care for surgical staging in patients with high-grade endometrial cancer.
引用
- Marchocki Z, Cusimano MC, Clarfield L, et al. Sentinel lymph node biopsy in high-grade endometrial cancer: a systematic review and meta-analysis of performance characteristics. Am J Obstet Gynecol. 2021. PMID: 34058168. doi:10.1016/j.ajog.2021.05.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。